DRIVE held it's month 22 General Assembly meeting from March 23-24th 2017 at one of the oldest Universities in Europe, Utrecht University, Netherlands. The main focus of the meeting was...(read more)
Safeguarding the delivery of pancreatic islets for the treatment of diabetes
DRIVE aims to improve pancreatic islet transplant therapy for diabetes mellitus, a chronic disease characterised by high blood sugar due to a shortage of insulin. Transplant of insulin-producing pancreatic islets restores tight natural control of blood sugar, eliminating the need for multiple daily injections of insulin, that ultimately affect patient’s quality of life.
Despite its proven effectiveness among current treatments for diabetes, this therapy, which involves infusing purified human pancreatic islets from donor pancreases into the patient’s liver, suffers from poor survival and engraftment of transplanted islets in the hostile liver environment. As a result, multiple donor pancreases are necessary for a successful islet transplant, which limits the use of this therapy to a small percentage of “brittle” type 1 patients for whom daily insulin injections are not sufficient to control their diabetes.
DRIVE will also develop a minimally invasive injection catheter (“β-Cath”) and perform a series of pre-clinical studies on the integrated β-Gel/β-Shell/β-Cath system to assess its efficacy in vivo.